U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H22N6O2
Molecular Weight 414.4598
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOMELOTINIB

SMILES

O=C(NCC#N)C1=CC=C(C=C1)C2=NC(NC3=CC=C(C=C3)N4CCOCC4)=NC=C2

InChI

InChIKey=ZVHNDZWQTBEVRY-UHFFFAOYSA-N
InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)

HIDE SMILES / InChI
Molecular Formula C23H22N6O2
Molecular Weight 414.4598
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:21:43 UTC 2023
Edited
by admin
on Sat Dec 16 17:21:43 UTC 2023
Record UNII
6O01GMS00P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOMELOTINIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
MOMELOTINIB [USAN]
Common Name English
Momelotinib [WHO-DD]
Common Name English
CYT387
Code English
CYT-0387
Code English
CYT-387
Code English
CYT-11387
Common Name English
momelotinib [INN]
Common Name English
N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDE
Systematic Name English
GS-0387
Code English
Classification Tree Code System Code
NCI_THESAURUS C1967
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
FDA ORPHAN DRUG 311610
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
Code System Code Type Description
DRUG BANK
DB11763
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
NCI_THESAURUS
C88311
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
USAN
XX-160
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
INN
9480
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
FDA UNII
6O01GMS00P
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
EPA CompTox
DTXSID801026049
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
SMS_ID
100000163080
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
PUBCHEM
25062766
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
WIKIPEDIA
CYT387
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
ChEMBL
CHEMBL1078178
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
CHEBI
91407
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
CAS
1056634-68-4
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
EVMPD
SUB177206
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
Related Record Type Details
ACTIVIN RECEPTOR TYPE-1
TARGET -> INHIBITOR
TYROSINE-PROTEIN KINASE JAK1
TARGET -> INHIBITOR
Structure of Momelotinib Dihydrochloride
SALT/SOLVATE -> PARENT
CYTOCHROME P450 4F2
METABOLIC ENZYME -> SUBSTRATE
MINOR
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2J2
METABOLIC ENZYME -> SUBSTRATE
MINOR
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
TYROSINE-PROTEIN KINASE JAK2
TARGET -> INHIBITOR
IC50
CYTOCHROME P450 1A1
METABOLIC ENZYME -> SUBSTRATE
MINOR
NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2
TARGET -> INHIBITOR
IC50
Structure of MOMELOTINIB
EXCRETED UNCHANGED
AMOUNT EXCRETED
FECAL
Structure of MOMELOTINIB
EXCRETED UNCHANGED
MINOR
URINE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
Structure of Momelotinib dihydrochloride monohydrate
SALT/SOLVATE -> PARENT
TYROSINE-PROTEIN KINASE JAK3
TARGET->WEAK INHIBITOR
Related Record Type Details
Structure of 4-(2-(4-(3-OXOMORPHOLIN-4-YL)ANILINO)PYRIMIDIN-4-YL)BENZAMIDE
METABOLITE -> PARENT
URINE
Structure of BENZAMIDE, N-(2-AMINO-2-OXOETHYL)-4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-
METABOLITE -> PARENT
PLASMA
Structure of 2-(N-(CARBOXYMETHYL)-4-((4-(4-(CYANOMETHYLCARBAMOYL)PHENYL)PYRIMIDIN-2-YL)AMINO)ANILINO)ACETIC ACID
METABOLITE -> PARENT
PLASMA
Structure of N-(CYANOMETHYL)-4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE
METABOLITE ACTIVE -> PRODRUG
MAJOR
URINE
Structure of BENZAMIDE, N-(CYANOMETHYL)-4-(2-((4-((2-HYDROXYETHYL)AMINO)PHENYL)AMINO)-4-PYRIMIDINYL)-
METABOLITE -> PARENT
FECAL
Structure of BENZOIC ACID, 4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-
METABOLITE -> PARENT
URINE
Structure of 4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZOIC ACID
METABOLITE -> PARENT
M19 coelute with M33 (m/z = 431.1469, oxidative metabolite of MMB) in human feces.
FECAL
Structure of BENZAMIDE, N-(2-AMINO-2-OXOETHYL)-4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-
METABOLITE -> PARENT
URINE
Structure of N-(CYANOMETHYL)-4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE
METABOLITE ACTIVE -> PARENT
Metabolite M21 was 2- to 3-fold less active than MMB for inhibition of JAK1/2 and ACVR1 in vitro. However, on the basis of the PAI assessment, M21 is anticipated to contribute significantly to the pharmacological activity of MMB, not only as a JAK1/2 inhibitor but also as an ACVR1 inhibitor
MAJOR
PLASMA
Structure of N-(2-AMINO-2-OXO-ETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDE
METABOLITE -> PARENT
Structure of BENZOIC ACID, 4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-
METABOLITE -> PARENT
MAJOR
FECAL
Structure of N-(CYANOMETHYL)-4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE
METABOLITE ACTIVE -> PARENT
MAJOR
FECAL
Structure of BENZAMIDE, N-(2-AMINO-2-OXOETHYL)-4-(2-((4-(3-OXO-4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-
METABOLITE -> PARENT
FECAL
Structure of BENZAMIDE, N-(CYANOMETHYL)-4-(2-((4-((2-HYDROXYETHYL)AMINO)PHENYL)AMINO)-4-PYRIMIDINYL)-
METABOLITE -> PARENT
URINE
Structure of 4-[2-[(4-Aminophenyl)amino]-4-pyrimidinyl]-N-(cyanomethyl)benzamide
METABOLITE -> PARENT
Structure of 4-(2-(4-(3-OXOMORPHOLIN-4-YL)ANILINO)PYRIMIDIN-4-YL)BENZAMIDE
METABOLITE -> PARENT
PLASMA
Structure of 4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZOIC ACID
METABOLITE -> PARENT
PLASMA
Structure of 2-(N-(CARBOXYMETHYL)-4-((4-(4-(CYANOMETHYLCARBAMOYL)PHENYL)PYRIMIDIN-2-YL)AMINO)ANILINO)ACETIC ACID
METABOLITE -> PARENT
URINE
Structure of 2-(N-(CARBOXYMETHYL)-4-((4-(4-(CYANOMETHYLCARBAMOYL)PHENYL)PYRIMIDIN-2-YL)AMINO)ANILINO)ACETIC ACID
METABOLITE -> PARENT
FECAL
Related Record Type Details
Structure of MOMELOTINIB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966